Creso Pharma Limited
COPHF · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $176 | $7,984,396 | $50,268,443 | $46,262,823 |
| - Cash | $692 | $1,388 | $7,184 | $6,047 |
| + Debt | $9,646 | $6,671 | $0 | $3,256 |
| Enterprise Value | $9,130 | $7,989,679 | $50,261,258 | $46,260,031 |
| Revenue | $18,921 | $8,689 | $6,218 | $2,448 |
| % Growth | 117.8% | 39.7% | 154% | – |
| Gross Profit | $2,335 | $287 | -$401 | -$3,882 |
| % Margin | 12.3% | 3.3% | -6.4% | -158.6% |
| EBITDA | -$25,157 | -$17,618 | -$28,058 | -$16,487 |
| % Margin | -133% | -202.8% | -451.2% | -673.5% |
| Net Income | -$52,446 | -$32,782 | -$31,766 | -$37,577 |
| % Margin | -277.2% | -377.3% | -510.8% | -1,535.2% |
| EPS Diluted | 0 | -0.022 | -0.029 | -0.1 |
| % Growth | 100% | 22% | 71.3% | – |
| Operating Cash Flow | $0 | -$30,833 | -$22,378 | -$9,622 |
| Capital Expenditures | -$313 | -$348 | -$454 | -$429 |
| Free Cash Flow | -$8,454 | -$31,181 | -$22,832 | -$10,051 |